The US Food and Drug Administration (FDA) has approved Shionogi’s Cuvposa for the treatment of chronic severe drooling in paediatric patients with neurological conditions such as cerebral palsy.
The results of a Phase III trial showed that 75% of children and adolescents treated with Cuvposa experienced an improvement in symptoms, versus 11% who received placebo.
Go deeper with GlobalData
The most commonly reported adverse reactions of the liquid treatment were dry mouth, vomiting, constipation, flushing and nasal congestion.
Cuvposa reduces the rate of salivation by preventing stimulation of acetylcholine receptors located on certain peripheral tissues, including salivary glands.
It has orphan drug status and is available as a 1mg/5ml clear, cherry-flavoured oral solution.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
